Levofolic

Levoleucovorin Disodium, the active ingredient in Levofolic, is a folate analog (leucovorin) presented as a solution for injection for intravenous use. It is employed as an antineoplastic adjuvant to rescue normal cells from high‑dose methotrexate toxicity and to reduce side effects of antifolate chemotherapy in cancer patients.

GNH USA supplies Levofolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levofolic is a folate analog used in oncology supportive care to mitigate toxicity from antifolate agents and high‑dose methotrexate.

- Rescue therapy after high‑dose methotrexate: restores intracellular reduced folates, allowing normal cell recovery. - Reduction of toxicity from antifolate chemotherapy: lessens myelosuppression and mucosal damage caused by agents such as pemetrexed. - Supportive care in cancer treatment: improves tolerance of chemotherapy regimens by protecting healthy tissue.

Levofolic may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Vomiting - Flushing or warmth sensation - Mild hypotension - Headache - Transient fever

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Severe hypotension requiring intervention - Acute renal toxicity - Cardiac arrhythmias - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Pulmonary edema or severe respiratory distress

Before initiating Levofolic therapy, clinicians should consider several safety measures.

- Renal function: assess creatinine clearance and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes during treatment. - Concurrent antifolate therapy: avoid overlapping dosing schedules. - Pregnancy: use only when clearly needed, after risk‑benefit evaluation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofolic can interact with several drugs; awareness of the interaction level guides management.

Major Interactions (Avoid): - Methotrexate: concurrent use may diminish rescue effectiveness. - High‑dose folic acid supplements: may interfere with intended folate rescue.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents (e.g., cisplatin): monitor renal function closely. - Hepatotoxic drugs (e.g., azathioprine): observe liver parameters. - Other folate pathway inhibitors (e.g., pemetrexed): consider dose adjustments.